China’s drive to cut health-care costs is taking a toll on the profits of its drugmakers.

Nearly 70% of the 65 pharmaceutical manufacturers listed in China have flagged they’re likely to report slower profit growth for the first half of this year. That’s the most since 2016, data compiled by Bloomberg show. While some haven’t given reasons for the expected weakness, others have pinned it on Beijing’s zeal in slashing drug prices and curtailing the use of medicines with unclear efficacy.

For full text of this Bloomberg News article, please visit the following weblink:

https://www.bloomberg.com/news/articles/2019-07-24/chinese-drugmakers-warn-on-profits-as-government-overhaul-bites

This is not an article published by Pharma China, and please visit the above website links for the full text of the article. The availability of the article is under the control of its publisher. We may occationally keep a copy of the article offline, so subscribers who cannot access the article online can contact info@pharmachinaonline.com for further information.